The University at Buffalo has been awarded a five-year, $21.7 million Clinical and Translational Science Award (CTSA) from the National Center for Advancing Translational Sciences of the National Institutes of Health in recognition of the dramatic progress UB and its partners have made since 2015 when UB first received the CTSA.
The CTSA program is designed to develop innovative solutions that will improve the efficiency, quality and impact of the process for turning observations in the laboratory, clinic and community into interventions that improve the health of individuals and the public.
Renewal of the grant allows researchers and clinicians at UB and its partners in the Buffalo Translational Consortium to continue to innovate, speeding the development of new treatments for disease, reducing health disparities and allowing more Western New Yorkers to benefit from clinical research.
UB’s Clinical and Translational Research Center (CTRC) of the Jacobs School of Medicine and Biomedical Sciences functions as the hub of the Buffalo Translational Consortium, which includes the five UB health sciences schools, including the University at Buffalo School of Public Health and Health Professions; Roswell Park Comprehensive Cancer Center; and clinical, other research and community partners.
“Building on the successes UB achieved with the original award, the CTSA renewal grant enables our researchers to further their investigations into the most vexing health problems, advance critical medical breakthroughs from bench to bedside and — in fulfillment of our university mission — make a positive difference in the lives of people here in Western New York and across the state, the nation and our world,” UB president, Dr. Satish K. Tripathi said.Tags: Friday Letter Submission, Publish on February 21